• Aoki, T., Harada, Y., Matsubara, E., Suzuki, T., Oyama, T., Kasai, M., Uchida, T. & Ogura, M. (2012) Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Journal of Clinical Pharmacy and Therapeutics, 37, 729732.
  • Bussel, J.B., Kuter, D.J., Pullarkat, V., Lyons, R.M., Guo, M. & Nichol, J.L. (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 113, 21612171.
  • Cheng, G., Saleh, M.N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., Arning, M., Stone, N.L. & Bussel, J.B. (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, 377, 393402.
  • Erhardt, J.A., Erickson-Miller, C.L., Aivado, M., Abboud, M., Pillarisetti, K. & Toomey, J.R. (2009) Comparative analyses of the small molecule thrombopoietin receptor agonist Eltrombopag and thrombopoietin on in vitro platelet function. Experimental Hematolology, 37, 10301037.
  • Garnock-Jones, K.P. & Keam, S.J. (2009) Eltrombopag. Drugs, 69, 567576.
  • Kuter, D.J. (2011) Romiplostim. Cancer Treatment and Research, 157, 267288.
  • Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., Bussel, J.B., Cines, D.B., Chong, B.H., Cooper, N., Godeau, B., Lechner, K., Mazzucconi, M.G., McMillan, R., Sanz, M.A., Imbach, P., Blanchette, V., Kühne, T., Ruggeri, M. & George, J.N. (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 113, 23862393.
  • Van den Oudenrijn, S., De Haas, M. & Von dem Borne, A.E. (2001) Screening for c-mpl mutations in patients with congenital amegakaryocytic thrombocytopenia identifies a polymorphism. Blood, 97, 36753676.